Ipilimumab is a monoclonal antibody that functions as an immune checkpoint inhibitor, primarily targeting the cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). This mechanism enhances the immune system's ability to recognize and attack cancer cells. Ipilimumab is primarily used in the treatment of melanoma, particularly in advanced stages, and has shown efficacy in improving overall survival rates in patients. The substance is administered via intravenous infusion and is characterized by its complex protein structure, which is typical of monoclonal antibodies. Its pharmacokinetics involve a long half-life, allowing for less frequent dosing compared to traditional chemotherapy agents. Common side effects may include immune-related adverse events due to heightened immune activity, affecting various organ systems. Ipilimumab's development marked a significant advancement in cancer immunotherapy, contributing to the growing field of targeted cancer treatments that leverage the body's immune system to combat malignancies.

Ipilimumab

477202-00-9: Ipilimumab is a monoclonal antibody that functions as an immune checkpoint inhibitor, primarily targeting the cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). This mechanism enhances the immune system's ability to recognize and attack cancer cells. Ipilimumab is primarily used in the treatment of melanoma, particularly in advanced stages, and has shown efficacy in improving overall survival rates in patients. The substance is administered via intravenous infusion and is characterized by its complex protein structure, which is typical of monoclonal antibodies. Its pharmacokinetics involve a long half-life, allowing for less frequent dosing compared to traditional chemotherapy agents. Common side effects may include immune-related adverse events due to heightened immune activity, affecting various organ systems. Ipilimumab's development marked a significant advancement in cancer immunotherapy, contributing to the growing field of targeted cancer treatments that leverage the body's immune system to combat malignancies.

<p>Ipilimumab (anti-CTLA-4) is an immunomodulatory monoclonal antibody directed against the cell surface antigen CTLA-4 and also a type of immune checkpoint</p>

<p>Monoclonal antibody against CTLA-4</p>

CAS 477202-00-9

Ipilimumab

Ipilimumab

Ref: TM-T9906

Ipilimumab

Ref: 3D-BI164048